Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection.

GLP-1 patches, topical adhesive patches worn on your arm or abdomen that claim to deliver natural weight-loss revving ...

The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave ...

"We are extremely encouraged by the interim results received to date aligned with our primary study endpoint," said Richard Christopher, CEO of Lexaria. "DehydraTECH is continuing to demonstrate ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

The diabetes and weight loss drug semaglutide may also reverse signs of liver disease. That’s the headline result of a new clinical trial that tested the popular medication in patients with MASH ...

Perhaps most reassuring about semaglutide’s cardiovascular benefits is their durability over time. The protection against major adverse cardiac events persisted throughout the study’s follow ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial. As Healio previously ...

Arun J. Sanyal, Philip N. Newsome, Iris Kliers, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis, New England Journal of Medicine (2025), DOI: 10.1056 ...

King's College London. "Semaglutide treats liver disease in two thirds of patients." ScienceDaily. ScienceDaily, 4 May 2025. <www.sciencedaily.com / releases / 2025 / 04 / 250430182815.htm>.

Shares of Hims Hers Health Inc (NYSE:HIMS) fell more than 3% early Tuesday before paring losses to around 0.2% in afternoon trade, after rising legal risks and a data disclosure drove swings in ...